ND-003

· Shenzhen NewDEL Biotech, Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ND-003, covering 2024-11-15 to 2024-11-15. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers [Phase 1]

See pricing